Anti-Alzheimer’s Disease activity: In vitro cholinesterase enzymes [(AChE) and (BChE)] inhibitory activitiesAChE1: IC50 = 1.31 ± 0.17 μM2: IC50 = 1.84 ± 0.19 μM3: IC50 = 1.94 ± 0.27 μM5: IC50 = 6.44 ± 0.85 μM24: IC50 = 12.66 ± 1.48 μM25: IC50 = 30.67 ± 8.14 μMPhysostigmine (positive control): IC50 = 0.08 ± 0.02 μMBChE1: IC50 = 39.21 ± 3.46 μM2: IC50 = 1.76 ± 0.21 μM3: IC50 = 2.80 ± 0.49 μM5: IC50 = 6.65 ± 0.13 μM24: IC50 = 10.51 ± 2.07 μM25: IC50 = 12.52 ± 2.86 μMPhysostigmine (positive control): IC50 = 0.22 ± 0.02 μMKiAChE and KiBChE2: 4.33 μM and 0.56 μM3: 5.86 μM and 11.46 μM. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.